Single Antiplatelet Therapy Halves Mortality and Bleeding Risk in TAVR Patients: Study
Findings from the Transfusion Requirements in Transcatheter Aortic Valve Implantation (TRITAVI) registry demonstrate that single antiplatelet therapy (SAPT) after transcatheter aortic valve replacement (TAVR) is associated with a significantly lower incidence of six-month mortality and major bleeding risk compared to dual antiplatelet therapy (DAPT). The late-breaking data were presented today at the Society for Cardiovascular Angiography & Interventions (SCAI) 2025 Scientific Sessions.
The current standard of care following TAVR is SAPT, which involves the use of only one antiplatelet drug, such as aspirin, to prevent blood clot formation. Traditionally, SAPT is used compared to DAPT, mainly based on the lower bleeding risk; however, the data on mortality are inconclusive. This insight is increasingly important as the number of TAVR procedures performed has steadily increased, making it the most common procedure for patients with aortic stenosis.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.